<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01662505</url>
  </required_header>
  <id_info>
    <org_study_id>1230.26</org_study_id>
    <nct_id>NCT01662505</nct_id>
  </id_info>
  <brief_title>Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate safety, tolerability, maximum tolerated dose of volasertib in Japanese
      patients with AML
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the maximum tolerated dose based on the incidence of dose limiting toxicities</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission (CR)</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission with incomplete blood count recovery (CRi)</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial remission (PR)</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Volasertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive escalating dose of volasertib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Volasertib</intervention_name>
    <description>Patient to receive volasertib</description>
    <arm_group_label>Volasertib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients with diagnosis of AML (except for acute promyelocytic leukemia, APL)
             according to the World Health Organization definition and with one of the following
             features at screening

               -  Relapsed or refractory AML

               -  Untreated AML patients not considered to be suitable for standard induction
                  therapy according to investigator's judgement

          2. Male or female patients of age &gt;/= 18 years at the time of informed consent

          3. Eastern Cooperative Oncology Group performance status score 0 - 2 at screening

          4. Signed written informed consent consistent with Japanese Good Clinical Practice.

        Exclusion criteria:

          1. Patients with APL

          2. Patients in the third or later relapse

          3. Prior stem cell transplantation

          4. Treatment with systemic therapy for the primary disease (including an investigational
             drug) within 14 days before the first dose of volasertib with the exception of
             hydroxyurea, or lack of recovery from any acute toxicities or clinically significant
             adverse events pertinent to the prior systemic therapy

          5. Treatment with gemtuzumab ozogamicin within 6 weeks before the first dose of
             volasertib

          6. Concomitant medication/treatment with anti-leukemic chemotherapy (systemic or
             intrathecal), radiotherapy, immunotherapy, or any investigational agent while
             receiving study treatment

          7. Other malignancy requiring treatment at the time of screening

          8. Clinical central nervous system (CNS) symptoms deemed by the investigator to be
             related to leukemic CNS involvement or requiring treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1230.26.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.26.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Isehara, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.26.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maebashi, Gunma,</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.26.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagasaki, Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.26.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya-shi, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.26.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yoshida-gun, Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2012</study_first_submitted>
  <study_first_submitted_qc>August 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2012</study_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 23, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

